PubMed Health⌕ Search

PubMed · 3788131

Exercise tests and ventricular tachycardia.

Abstract

All treadmill exercise tests done at the Palo Alto Veterans Administration Medical Center from 1973 to 1982 were reviewed to identify episodes of ventricular tachycardia (>/=3 consecutive ventricular ectopic complexes) or ventricular fibrillation occurring during or within 8 minutes of cessation of symptom-limited exercise. Of patients with a clinical diagnosis of coronary artery disease (900 tests), ventricular tachycardia occurred in 36 (4.0%) and ventricular fibrillation in 6 (0.7%). Of patients without known coronary disease (1,700 tests), ventricular tachycardia occurred in 12 (0.07%), and no patient had ventricular fibrillation. Most arrhythmias ceased spontaneously and only 5 patients required cardioversion. We conclude that exercise tests are safe, the incidence of ventricular tachycardia or ventricular fibrillation is low-these arrhythmias occurring largely in patients with known coronary disease-spontaneous return to sinus rhythm is common and no deaths were associated with 2,400 consecutive tests.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Milanes, M Romero, H N Hultgren, U Shettigar. 1986. Exercise tests and ventricular tachycardia.. https://pubmed.ncbi.nlm.nih.gov/3788131/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗